TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Feasibility of assessment of NGEU and esophageal muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichlorofluorescein fluorescence slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain on Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of individuals with Smith-Magenis syndrome
Endpoint domain: Mortality/survival
Primary endpoint: Number of subjects with treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with a relapse and/or progressive worsening of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prepulse Inhibition of the Startle Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P50 Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P300 ERP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mismatch Negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Topographical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of change in cardiac strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Lice-free Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Major adverse cardiovascular outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Surgical visibility of abdomen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lowest pneumoperitoneum pressure (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lowest Trendelenburg inclination angle (TIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Pain Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: frequency of vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropathic Pain Inventory Scale (NPIS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Maximal keratometry (Kmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rate of non-responders regarding ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerability and side effects of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOL) interviews
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite of all fatal or non-fatal major cardiovascular/cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aggressive behavior score variation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Investigator Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Forced expiratory volume in 1 second / forced vital capacity (FEV1/FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Residual volume (VR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VR/total lung capacity (TLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participants' performance on adult ADHD rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma level of VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma level of procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: wound spread area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Voice Handicap Index (VHI-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Drinks Per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From First Event Requiring ICD Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neuronal cell death marker levels of NSE and S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in mean weight in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mean calorie intake (kcal/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mean calorie expenditure (kcal/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subject Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative incidence of symptomatic brain metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Surgical Site Infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Weight Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of Gravity Displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of Pressure Displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weber test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACT-Gastric Trial Outcome Index (TOI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Chinese version of Edmonton symptom assessment scale (C-ESAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sustained/symptomatic ventricular tachycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Drug Reaction (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Iron transfer from the mother to the fetus in cord blood/infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infants iron status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expression of Wnt pathway target genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cellular localization of beta-catenin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in lower extremity muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in indices of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: optic nerve sheath change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 30 day Glasgow outcome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day modified Rankin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic values of EBUS-TBNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants receiving best-medical-treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Axillary tumoral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intubation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ischemic or hemorrhagic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Return to work, duration
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Well-being and Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical function at 16 weeks post THA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in severity of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous thrombin potential by Thrombin Generation Assay (TGA)-2a assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of fibrin degradation product (D-dimer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of fibrinopeptide A (FPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Approval of prosocial motivation to organ donation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and seriousness of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in vital signs and laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Nanoxel M injection
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gene expression of subcutaneous adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evans Grade Histopathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: American College of Rheumatology 20% Response Rate (ACR20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Repeatability of bolus-dose inhalative allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Ability to acquire EMG signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful transmission of analysis to the base station
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification and transmission of alert conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical risk literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resource Utilization Pattern
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dosing Pattern
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in the Hamilton Depression Rating Scale (HAMDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Simple Clinical Colitis Disease Activity (SCCAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Utilization of a second uterotonic drug
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Vitamin D serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Treated Patients With Average Serum Testosterone Concentrations Between 300 and 1000 ng/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak Change on Drug Effects Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in maternal sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in infant behavioral regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System Usability Scale (SUS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal Voluntary Quadriceps Force [% Change From Baseline]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Influenza Virus Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of Influenza Virus Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Touching sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUCτ of telmisartan, amlodipine, atorvastatin, 2-OH atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,max of telmisartan, amlodipine, atorvastatin, 2-OH atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic fibrosis stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Sensitive cutaneous block distribution area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Addenbrooke's Cognitive Examination III (ACE-III) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median prediction error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Severe Asthma Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Change From Baseline in CRP Levels at Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least 1-point Improvement in Clinical Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Score in Self-assessment of Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: humoral parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cancer-related biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory and cognition (ADAS-cog/MCI and CDR-SB scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global functional skills and overall severity of dementia (CDR-SB and overall CDR)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of drug resistance-linked genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sinus floor height change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete abortion requiring no further medical or surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Height and width of bone gained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone area percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the ACR Revised CRISS at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The proportion of participants who experience at least one Grade 3 or higher adverse event at or before 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of Calories Selected and Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median effect concentration of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric/Behavioral Crisis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overdose of Drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Clearance of Actinic Keratoses (AK) Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: WH-PACT Achievement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Experienced Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Non-progression Rate at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cmax: Maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to reach the peak plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2: Elimination half-life of plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new cases of Pompe disease diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe vasoplegia
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of pleural drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of Norovirus Gastroenteritis
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of de-worming treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee joint angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: moment of knee flexion in the gait cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: moment of knee extension in the gait cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual analog pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTcF interval values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial Glucose (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PostPrandial Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of accurate liver surface registrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fractional aneurysm sac size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HLA Type Determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polymorphisms in the FVII Gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment success or failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease activity score (DAS28, SDAI, CDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage Change in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurence of pancreatic fistula leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in serum syndecan 1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum heparan sulfate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of distal hair growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tendon Structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tendon Mechanical Properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes